1566 related articles for article (PubMed ID: 26842476)
1. Development of Broadly Neutralizing Antibodies and Their Mapping by Monomeric gp120 in Human Immunodeficiency Virus Type 1-Infected Humans and Simian-Human Immunodeficiency Virus SHIVSF162P3N-Infected Macaques.
Jia M; Lu H; Markowitz M; Cheng-Mayer C; Wu X
J Virol; 2016 Apr; 90(8):4017-4031. PubMed ID: 26842476
[TBL] [Abstract][Full Text] [Related]
2. Gp120 V5 Is Targeted by the First Wave of Sequential Neutralizing Antibodies in SHIV
Jia M; Lu H; Kong XP; Cheng-Mayer C; Wu X
Viruses; 2018 May; 10(5):. PubMed ID: 29772652
[TBL] [Abstract][Full Text] [Related]
3. A Trimeric HIV-1 Envelope gp120 Immunogen Induces Potent and Broad Anti-V1V2 Loop Antibodies against HIV-1 in Rabbits and Rhesus Macaques.
Jones AT; Chamcha V; Kesavardhana S; Shen X; Beaumont D; Das R; Wyatt LS; LaBranche CC; Stanfield-Oakley S; Ferrari G; Montefiori DC; Moss B; Tomaras GD; Varadarajan R; Amara RR
J Virol; 2018 Mar; 92(5):. PubMed ID: 29237847
[TBL] [Abstract][Full Text] [Related]
4. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 Cross-Reactive Primary Virus Neutralizing Antibody Response Elicited by Immunization in Nonhuman Primates.
Wang Y; O'Dell S; Turner HL; Chiang CI; Lei L; Guenaga J; Wilson R; Martinez-Murillo P; Doria-Rose N; Ward AB; Mascola JR; Wyatt RT; Karlsson Hedestam GB; Li Y
J Virol; 2017 Nov; 91(21):. PubMed ID: 28835491
[TBL] [Abstract][Full Text] [Related]
6. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection.
Derby NR; Kraft Z; Kan E; Crooks ET; Barnett SW; Srivastava IK; Binley JM; Stamatatos L
J Virol; 2006 Sep; 80(17):8745-62. PubMed ID: 16912322
[TBL] [Abstract][Full Text] [Related]
7. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
[TBL] [Abstract][Full Text] [Related]
8. Development of broad neutralization activity in simian/human immunodeficiency virus-infected rhesus macaques after long-term infection.
Gao N; Wang W; Wang C; Gu T; Guo R; Yu B; Kong W; Qin C; Giorgi EE; Chen Z; Townsley S; Hu SL; Yu X; Gao F
AIDS; 2018 Mar; 32(5):555-563. PubMed ID: 29239895
[TBL] [Abstract][Full Text] [Related]
9. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques.
Gao N; Gai Y; Meng L; Wang C; Zhang X; Wang W; Qin C; Yu X; Gao F
Viruses; 2020 Jan; 12(2):. PubMed ID: 32023860
[TBL] [Abstract][Full Text] [Related]
10. Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.
Someya K; Cecilia D; Ami Y; Nakasone T; Matsuo K; Burda S; Yamamoto H; Yoshino N; Kaizu M; Ando S; Okuda K; Zolla-Pazner S; Yamazaki S; Yamamoto N; Honda M
J Virol; 2005 Feb; 79(3):1452-62. PubMed ID: 15650171
[TBL] [Abstract][Full Text] [Related]
11. Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge of macaques compared with a strongly neutralizing antibody.
Burton DR; Hessell AJ; Keele BF; Klasse PJ; Ketas TA; Moldt B; Dunlop DC; Poignard P; Doyle LA; Cavacini L; Veazey RS; Moore JP
Proc Natl Acad Sci U S A; 2011 Jul; 108(27):11181-6. PubMed ID: 21690411
[TBL] [Abstract][Full Text] [Related]
12. Rapid development of glycan-specific, broad, and potent anti-HIV-1 gp120 neutralizing antibodies in an R5 SIV/HIV chimeric virus infected macaque.
Walker LM; Sok D; Nishimura Y; Donau O; Sadjadpour R; Gautam R; Shingai M; Pejchal R; Ramos A; Simek MD; Geng Y; Wilson IA; Poignard P; Martin MA; Burton DR
Proc Natl Acad Sci U S A; 2011 Dec; 108(50):20125-9. PubMed ID: 22123961
[TBL] [Abstract][Full Text] [Related]
13. Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs.
Bolton DL; Pegu A; Wang K; McGinnis K; Nason M; Foulds K; Letukas V; Schmidt SD; Chen X; Todd JP; Lifson JD; Rao S; Michael NL; Robb ML; Mascola JR; Koup RA
J Virol; 2016 Feb; 90(3):1321-32. PubMed ID: 26581981
[TBL] [Abstract][Full Text] [Related]
14. SOSIP Trimer-Specific Antibodies Isolated from a Simian-Human Immunodeficiency Virus-Infected Monkey with versus without a Pre-blocking Step with gp41.
Duggan NN; Weisgrau KL; Magnani DM; Rakasz EG; Desrosiers RC; Martinez-Navio JM
J Virol; 2022 Jan; 96(2):e0158221. PubMed ID: 34730398
[TBL] [Abstract][Full Text] [Related]
15. Rapid Elimination of Broadly Neutralizing Antibodies Correlates with Treatment Failure in the Acute Phase of Simian-Human Immunodeficiency Virus Infection.
Wu Y; Xue J; Wang C; Li W; Wang L; Chen W; Prabakaran P; Kong D; Jin Y; Hu D; Wang Y; Lei C; Yu D; Tu C; Bardhi A; Sidorov I; Ma L; Goldstein H; Qin C; Lu L; Jiang S; Dimitrov DS; Ying T
J Virol; 2019 Oct; 93(20):. PubMed ID: 31375583
[TBL] [Abstract][Full Text] [Related]
16. Evolution of cross-neutralizing antibodies and mapping epitope specificity in plasma of chronic HIV-1-infected antiretroviral therapy-naïve children from India.
Makhdoomi MA; Khan L; Kumar S; Aggarwal H; Singh R; Lodha R; Singla M; Das BK; Kabra SK; Luthra K
J Gen Virol; 2017 Jul; 98(7):1879-1891. PubMed ID: 28696188
[TBL] [Abstract][Full Text] [Related]
17. The C3/465 glycan hole cluster in BG505 HIV-1 envelope is the major neutralizing target involved in preventing mucosal SHIV infection.
Charles TP; Burton SL; Arunachalam PS; Cottrell CA; Sewall LM; Bollimpelli VS; Gangadhara S; Dey AK; Ward AB; Shaw GM; Hunter E; Amara RR; Pulendran B; van Gils MJ; Derdeyn CA
PLoS Pathog; 2021 Feb; 17(2):e1009257. PubMed ID: 33556148
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of immune responses induced by HIV-1 gp120 in rhesus macaques: effect of vaccination on challenge with pathogenic strains of homologous and heterologous simian human immunodeficiency viruses.
Kumar A; Lifson JD; Silverstein PS; Jia F; Sheffer D; Li Z; Narayan O
Virology; 2000 Aug; 274(1):149-64. PubMed ID: 10936096
[TBL] [Abstract][Full Text] [Related]
19. Quaternary epitope specificities of anti-HIV-1 neutralizing antibodies generated in rhesus macaques infected by the simian/human immunodeficiency virus SHIVSF162P4.
Robinson JE; Franco K; Elliott DH; Maher MJ; Reyna A; Montefiori DC; Zolla-Pazner S; Gorny MK; Kraft Z; Stamatatos L
J Virol; 2010 Apr; 84(7):3443-53. PubMed ID: 20106929
[TBL] [Abstract][Full Text] [Related]
20. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
